- 期刊
- OpenAccess
Factors Affecting Quality of Life Among Patients with Advanced Prostate Cancer Undergoing Hormonal Therapy
影響接受荷爾蒙治療的晚期前列腺癌患者生活品質的因素
摘要
This study aimed to analyze quality of life (QOL) in advanced prostate cancer patients who are undergoing hormonal therapy (H/T) to assess major influencing factors and to develop a strategy to improve their QOL. This study enrolled 108 men with advanced prostate cancer aged 43 to 98 years old (median = 74) who had been receiving androgen deprivation therapy for six months to seven years; this therapy consisted of luteinizing hormone-releasing hormone (LHRH) agonists, anti-androgen agents alone, or a combination administered at a single medical center. We used the 47-item Functional Assessment of Cancer Therapy-Prostate (FACT-P, version 3) questionnaire, which was translated into Chinese. The completion rate was 100% using one-on-one and face-to-face interviewing methods. We analyzed the relationship between QOL and the diagnostic age, therapeutic duration, modality of H/T, tumor stage, and therapeutic result. The results concluded that changes in the serum prostate-specific antigen (PSA) level significantly influenced QOL. A better therapeutic result promotes higher FACT-P scores. Although PSA elevation during H/T usually indicates disease progression, it seldom affects the physical condition initially. Nevertheless, increased PSA levels did reduce the total QOL scores according to our study results. Therefore, adequately informing our patients about the relationship between the PSA level and the clinical course of disease progression including salvage strategy for biochemical failure was suggested to minimize their significant fears of an uncertain future and thus improve their QOL during standard H/T for prostate cancer.
並列摘要
本研究分析正在接受荷爾蒙治療（又稱為雄激素剝奪治療）的晚期前列腺癌患者的生活品質，以評估主要影響因素並制定改善其生活品質的策略。這項研究納入了108名患有晚期前列腺癌的男性，年齡為43至98歲（中位數= 74歲），他們接受了6個月至7年的荷爾蒙治療治療，其中包括促黃體激素釋放激素激動劑，抗雄激素單獨的藥劑或合併促黃體激素釋放激素激動劑及抗雄激素。我們使用了47項問卷的癌症治療功能評估－前列腺（第3版）中文版。完成率為100％，採用研究護理師對病患逐個面對面的問卷方法。我們分析了生活品質與診斷年齡，治療時間，激素治療方式，腫瘤分期和治療結果之間的關係。結論是血清前列腺特異性抗原值的變化顯著影響生活品質。較好的治療效果可提高癌症治療功能評估評分。雖然荷爾蒙治療治療期間的前列腺特定抗原升高通常代表疾病進展，但它最初很少影響身體狀況。然而，根據我們的研究，它確實惡化了整體生活品質分數。因此，建議我們的患者了解前列腺特定抗原數值與疾病進展的臨床過程之間的關係，包括生化指數復發的挽救策略，以盡量減少他們對不確定未來的巨大恐懼，從而對於前列腺癌標準激素治療期間提高他們的生活品質。